Fermenta Biotech

Fermenta Biotech Retained Earnings

The Retained Earnings of Fermenta Biotech (506414.BO) as of Oct 22, 2026 is 3.50 B INR. In the previous year, Retained Earnings was 2.63 B INR — a change of 33.18% (higher).

Retained Earnings

3.50 BINR

YoY

33.18%

Last updated:

Retained Earnings of Fermenta Biotech is 2025 3.50 B INR. Retained Earnings of Fermenta Biotech was 2024 2.63 B INR. It decreases by 33.18% higher compared to the previous year.

The Fermenta Biotech Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
1.22 B INR
Jan 1, 2019
2.45 B INR
Jan 1, 2020
2.89 B INR
Jan 1, 2021
3.34 B INR
Jan 1, 2022
3.42 B INR
Jan 1, 2023
2.88 B INR
Jan 1, 2024
2.63 B INR
Jan 1, 2025
3.50 B INR
The Fermenta Biotech Retained Earnings history
YEARRetained EarningsYoY
3.50 BINR+33.18%
2.63 BINR-8.68%
2.88 BINR-15.92%
3.42 BINR+2.39%
3.34 BINR+15.75%
2.89 BINR+17.83%
2.45 BINR+100.64%
1.22 BINR+5.74%
1.16 BINR+9.58%
1.05 BINR-1.70%
1.07 BINR-0.95%
1.08 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fermenta Biotech Stock analysis

What does Fermenta Biotech do? Fermenta Biotech Ltd manufactures and supplies Vitamin D3, operating through its Chemicals/Bulk Drug segment that produces bulk drugs and enzymes for pharmaceuticals, dietary supplements, food fortification, animal feed, veterinary, and rodenticide industries. The Property segment generates revenue by renting and selling properties. The company's proprietary enzyme portfolio supports biopharmaceutical product development, while its nutritional ingredients include fish oil-derived cholesterol for aquaculture, natural astaxanthin, and vitamin AD2 premix, all sold to customers in the specified sectors. The Chemicals/Bulk Drug segment serves pharmaceutical, dietary supplement, food and beverage, animal feed, veterinary, and rodenticide markets with bulk drugs and enzymes. The Property segment focuses on real estate transactions, providing rental and sales services for its properties. Fermenta Biotech's product portfolio targets industries requiring specialized biopharmaceutical technologies and nutritional supplements, with key offerings like Vitamin D3, fish oil cholesterol, astaxanthin, and vitamin AD2 premix directly sold to these sectors. Fermenta Biotech Ltd's revenue streams come from the sale of Vitamin D3 and other bulk drugs through its Chemicals/Bulk Drug segment, while the Property segment contributes through property rentals and sales. The company's nutritional ingredients, such as fish oil-derived cholesterol, natural astaxanthin, and vitamin AD2 premix, are sold to industries including pharmaceuticals, dietary supplements, food fortification, animal feed, and veterinary sectors, with no additional brand or customer details provided beyond the business description. Fermenta Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fermenta Biotech stock

Retained Earnings of Fermenta Biotech is 3.50 B INR in 2025.

Retained Earnings of Fermenta Biotech changed from 2.63 B INR to 3.50 B INR, representing a 33.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Fermenta Biotech since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Fermenta Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fermenta Biotech

All Key Metrics — Fermenta Biotech